You just read:

Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia

News provided by

Eiger BioPharmaceuticals, Inc.

Apr 18, 2017, 08:00 ET